Shares of Sai Parenteral made a subdued debut on the stock exchanges on Thursday, April 2, 2026. The stock listed at a marginal premium compared to its issue price, reflecting cautious investor sentiment.
The listing performance remained modest across both the National Stock Exchange and the BSE. The IPO had received limited overall subscription, which was reflected in the listing outcome.
Sai Parenteral shares opened at ₹400 per share on the National Stock Exchange, registering a premium of 2.04% over the issue price of ₹392. On the BSE, the stock debuted slightly higher at ₹405, indicating a gain of 3.32%. The difference in listing prices across exchanges reflected marginal variation in initial demand. The overall listing performance remained within a narrow range.
The ₹408.79 crore initial public offering comprised both fresh issue and offer-for-sale components. The fresh issue aggregated to ₹285 crore, while the OFS component totalled ₹123.79 crore.
The IPO was priced in the band of ₹201 to ₹212 per share. The final issue price was fixed at ₹392 per share. The proceeds from the fresh issue are allocated across multiple strategic areas.
The IPO was subscribed 1.05 times overall, indicating moderate demand. Investor participation varied significantly across categories.
Qualified Institutional Buyers and Non-Institutional Investors showed relatively stronger interest. Retail participation remained notably weak.
| Category | Shares Offered | Shares Bid | Subscription (Times) |
| QIB | 21,12,900 | 36,10,266 | 1.71 |
| NII | 16,22,876 | 38,31,502 | 2.36 |
| Retail | 37,86,710 | 4,39,204 | 0.12 |
| Total | 75,22,486 | 78,80,972 | 1.05 |
Sai Parenteral is a diversified pharmaceutical formulations company with capabilities in both research and development and manufacturing. It operates in CDMO services as well as branded generic formulations, serving domestic and international markets.
Its product portfolio covers key therapeutic areas including anti-diabetic, cardiovascular, respiratory, antibiotics, gastroenterology, vitamins and supplements, neuropsychiatry and dermatology. This diversification supports revenue generation across multiple healthcare segments and reduces dependence on any single category.
Read More: Sun Pharma Share Price in Focus.
Sai Parenteral’s stock market debut reflected a modest listing performance with limited gains over the issue price. The IPO saw moderate overall subscription, driven primarily by institutional investors.
Retail participation remained weak, which may have influenced listing sentiment. The company operates in a diversified pharmaceutical segment with presence across multiple therapeutic areas and business models.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 2, 2026, 10:42 AM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
